Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity (Q36717363)

15 August 2017

1 reference

title

Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity (English)

1 reference

15 August 2017

Filippo Montemurro

1

1 reference

15 August 2017

Giorgio Valabrega

series ordinal

2

1 reference

15 August 2017

Massimo Aglietta

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Biological Therapy

15 August 2017

1 reference

15 August 2017

7

1 reference

15 August 2017

2

1 reference

15 August 2017

257-268

1 reference

Untangling the ErbB signalling network

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Trastuzumab-based combination therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Her2-targeted therapies in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Trastuzumab-associated cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.257

21 January 2018

Identifiers

DOI

10.1517/14712598.7.2.257

1 reference

15 August 2017

1 reference